Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the long-term efficacy and safety of once
daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat®
inhaler, in patients with COPD.